Abstract
Background Psychiatric disorders cause substantial patient suffering world-wide, which could be alleviated through the discovery of early diagnostic biomarkers. Urinary markers have promising practical applications; however, no robust urine biomarkers exist currently for psychiatric disorders. While the traditional biomarker discovery process is costly and time-consuming, genetic methods utilizing existing data from large-scale studies, such as Mendelian randomization, may provide an alternative, cost-effective approach to identifying such biomarkers.
Methods A two-sample Mendelian randomization analysis was conducted in R using GWAS data for seven psychiatric disorders from the Psychiatrics Genomics Consortium, as well as a meta-analysis of urinary metabolite GWAS studies and the GWAS Catalog. Mendelian randomization assumptions were assessed using the MR-Egger intercept, P-values, and genetic associations from the PhenoScanner database.
Outcomes The Mendelian randomization analysis revealed 67 analyte-disorder associations, of which 21 were exclusive to a single disorder. Most notable associations were observed between tyrosine and schizophrenia (β=−0.041, SE=0.013, Q=0.027), and creatine and bipolar disorder (β=−0.077, SE=0.019, Q=0.002), which validated across multiple studies, as well as that of pyridoxal (β=0.10, SE=0.03, Q=0.042) and ferulic acid 4-sulfate (β=0.077, SE=0.025, Q=0.037) to anorexia nervosa, and N,N-dimethylglycine to attention deficit hyperactivity disorder (β=−0.39, SE=0.11, Q=0.008).
Interpretation These results indicate an association between bipolar disorder, schizophrenia, anorexia nervosa, and attention deficit hyperactivity disorder with urinary metabolite marker alterations. Most of the findings were supported by previous literature. The results provide a roadmap for future experimental and clinical validation of the identified biomarker candidates and demonstrate the utility of using genetic instruments for urinary biomarker discovery.
Competing Interest Statement
SB is a director of Psynova Neurotech Ltd and Psyomics Ltd and has financial interests in Psyomics Ltd. The remaining authors declare no competing interests.
Funding Statement
This work was supported by the Stanley Medical Research Institute (grant number: 12T-008) by grants to S.B, and by the Oskar Huttunen Foundation grant to JKZ.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in this study is available from the corresponding authors upon reasonable request.
